In addition to the efficacy of tumor reduction noted through siRNA interference and the use of survivin-specific inhibitors, vaccine conjugate therapy dedicated to the inhibitor of apoptosis protein possesses considerable potential in priming the immune system against survivin and reducing the radioresistant qualities inherent to the malignancy. Here, BIRC5 is linked to neoplasm.